Implementing a drug interaction protocol for oral systemic anti-cancer therapy with focus on CDK4/6 inhibitors.
Calvin R. Flynn, Eileen M. McMahon, Shahid Iqbal, Karen McLoughlin et autres
302 Background: Oral anti-cancer therapies (OACTs) are being increasingly used. Despite their convenience, OACTs introduce challenges with adherence, prescribing errors, and high incidence of drug-drug interactions (DDIs). Currently, there are limited guidelines for DDI checking. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have revolutionized …
ie (code pays fourni par la source)
2 citations
JCO Oncology Practice